Drug Profile


Alternative Names: COL-144; LY-573144

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly; Lundbeck A/S
  • Developer CoLucid Pharmaceuticals
  • Class Antimigraines; Benzamides; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1F receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 18 Aug 2017 Eli Lilly plans a phase I trial in Healthy volunteers in USA (NCT03252015)
  • 17 Aug 2017 Eli Lilly plans a phase I trial for Migraine (In volunteers) in USA (NCT03247790)
  • 04 Aug 2017 Eli Lilly announces intention to submit NDA to the US FDA for Migraine in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top